EUVIMEDTutustu EUVIMEDiin
Crossref

Changes in the tumour microenvironment mark the transition from serous borderline tumour to low‐grade serous carcinoma

Rodrigo Vallejos iD, Almira Zhantuyakova, Gian Luca Negri iD, Spencer D Martin, Sandra E Spencer, Shelby Thornton, Samuel Leung, Branden Lynch iD, Yimei Qin, Christine Chow, Brooke Liang, Sabrina Zdravko and 12 more

The Journal of Pathology · 2024

DOI: 10.1002/path.6338 ↗

At a glance

Journal article in The Journal of Pathology, 2024. Written by Rodrigo Vallejos and 23 co-authors. Institution: Department of Genome Sciences and Technology, University of British Columbia, Vancouver, BC, Canada. Major MEDLINE topics: Tumor Microenvironment, Ovarian Neoplasms, Cystadenocarcinoma, Serous. Cited 9 times so far (Crossref); 59 references. Funded by: U.S. Department of Defense, BC Cancer Foundation, VGH and UBC Hospital Foundations.

TiivistelmäSubjectsBibliografiset tiedotCiteRelated studies

Abstract (original language)

Low‐grade serous ovarian carcinoma (LGSC) is a rare and lethal subtype of ovarian cancer. LGSC is pathologically, biologically, and clinically distinct from the more common high‐grade serous ovarian carcinoma (HGSC). LGSC arises from serous borderline ovarian tumours (SBTs). The mechanism of transformation for SBTs to LGSC remains poorly understood. To better understand the biology of LGSC, we performed whole proteome profiling of formalin‐fixed, paraffin‐embedded tissue blocks of LGSC ( n = 11), HGSC ( n = 19), and SBTs ( n = 26). We identified that the whole proteome is able to distinguish between histotypes of the ovarian epithelial tumours. Proteins associated with the tumour microenvironment were differentially expressed between LGSC and SBTs. Fibroblast activation protein (FAP), a protein expressed in cancer‐associated fibroblasts, is the most differentially abundant protein in LGSC compared with SBT. Multiplex immunohistochemistry (IHC) for immune markers (CD20, CD79a, CD3, CD8, and CD68) was performed to determine the presence of B cells, T cells, and macrophages. The LGSC FAP + stroma was associated with greater abundance of Tregs and M2 macrophages, features not present in SBTs. Our proteomics cohort reveals that there are changes in the tumour microenvironment in LGSC compared with its putative precursor lesion, SBT. These changes suggest that the tumour microenvironment provides a supportive environment for LGSC tumourigenesis and progression. Thus, targeting the tumour microenvironment of LGSC may be a viable therapeutic strategy. © 2024 The Pathological Society of Great Britain and Ireland.

Subjects

MeSH terms (MEDLINE)

Tumor MicroenvironmentOvarian NeoplasmsCystadenocarcinoma, SerousHumansFemaleBiomarkers, TumorNeoplasm GradingDisease ProgressionProteomicsSerine EndopeptidasesMiddle AgedMembrane ProteinsGelatinasesAgedEndopeptidasesCancer-Associated FibroblastsLymphocytes, Tumor-InfiltratingFibroblast Activation Protein Alpha

Author keywords

T cellsfibroblast activation proteinfibroblastsimmunosuppressionlow‐grade serous ovarian carcinomamacrophagesmultiplex IHCregulatory T cellsserous borderline ovarian tumourstumour microenvironment

Substances

Biomarkers, TumorSerine EndopeptidasesMembrane ProteinsGelatinasesEndopeptidasesFibroblast Activation Protein Alpha

Authors and institutions

  • Department of Genome Sciences and Technology, University of British Columbia, Vancouver, BC, Canada.
  • Department of Molecular Oncology, BC Cancer, Vancouver, BC, Canada.
  • Department of Obstetrics and Gynaecology, University of British Columbia, Vancouver, BC, Canada.
  • Genome Sciences Centre, BC Cancer, Vancouver, BC, Canada.
  • Diagnostic and Molecular Pathology, University of British Columbia, Vancouver, BC, Canada.
  • Molecular and Advanced Pathology Core, University of British Columbia, Vancouver, BC, Canada.

ORCID profiles: Rodrigo Vallejos, Gian Luca Negri, Branden Lynch, Brooke E Howitt, David G Huntsman, Dawn Cochrane

Funding

  • U.S. Department of Defense
  • BC Cancer Foundation
  • VGH and UBC Hospital Foundations
  • Chew Wei Memorial Professorship
  • Canada Research Chairs Program
  • VGH and UBC Hospital Foundation

Cite

APA

Vallejos, R., Zhantuyakova, A., Negri, G. L., Martin, S. D., Spencer, S. E., Thornton, S., Leung, S., Lynch, B., Qin, Y., Chow, C., Liang, B., Zdravko, S., Douglas, J. M., Milne, K., Mateyko, B., Nelson, B. H., Howitt, B. E., Kommoss, F. K., Horn, L. C., …, & Cochrane, D. (2024). Changes in the tumour microenvironment mark the transition from serous borderline tumour to low‐grade serous carcinoma. The Journal of Pathology. https://doi.org/10.1002/path.6338

Vancouver

Vallejos R, Zhantuyakova A, Negri GL, Martin SD, Spencer SE, Thornton S, et al. Changes in the tumour microenvironment mark the transition from serous borderline tumour to low‐grade serous carcinoma. The Journal of Pathology. 2024. doi:10.1002/path.6338

BibTeX
@article{Vallejos2024,
  author = {Vallejos, Rodrigo and Zhantuyakova, Almira and Negri, Gian Luca and Martin, Spencer D and Spencer, Sandra E and Thornton, Shelby and Leung, Samuel and Lynch, Branden and Qin, Yimei and Chow, Christine and Liang, Brooke and Zdravko, Sabrina and Douglas, J Maxwell and Milne, Katy and Mateyko, Bridget and Nelson, Brad H and Howitt, Brooke E and Kommoss, Felix Kf and Horn, Lars-Christian and Hoang, Lien and Singh, Naveena and Morin, Gregg B and Huntsman, David G and Cochrane, Dawn},
  title = {Changes in the tumour microenvironment mark the transition from serous borderline tumour to low‐grade serous carcinoma},
  journal = {The Journal of Pathology},
  year = {2024},
  doi = {10.1002/path.6338}
}
Start for free →